摘要
背景:黄酮木脂素的属名在1968年被创立,它是一种相对较小的天然杂交分子,生物途径起源于无处不在的黄酮和木脂素类化合物(苯丙素)。 黄酮木脂素最先从长期用于肝保护的水飞蓟中萃取得到。近期黄酮木脂素的药用价值拓展到了前列腺癌管理。 方法:相关文献系统性阐述和总结 结果:目前已经从各种植物中获得了天然的超过40种黄酮木脂素。部分黄酮木脂素已经进行了体外细胞和体内动物试验以及人类临床试验,证实了其:(1)具有有效的拮抗各种肿瘤促进剂的化学预防能够;(2)表达出抗血管再生的有效性;(3)对前列腺癌潜在治疗作用;(4)保护或者治疗前列腺癌患者在化疗过程中引起的肝毒性。部分黄酮木脂素能够协同增加化疗作用治疗前列腺癌。 结论:本文对黄酮木脂素在前列腺癌管理方面的潜在前景提供了一个系统的、深入的综述,包括化学预防功能、化疗、作用机制、合成衍生物、构效关系以及黄酮木脂素和相似的独立黄酮两者对抑制前列腺癌细胞增加的不同点。本综述通过结合文献中报道的数据阐述,旨在为前列腺癌管理黄酮木脂素的进一步合理发展提供有价值的见解。
关键词: 前列腺癌;黄酮木脂素;作用机制;化疗制剂;构效关系;黄酮
Current Medicinal Chemistry
Title:The Potential of Flavonolignans in Prostate Cancer Management
Volume: 23 Issue: 34
Author(s): Bao Vue, Qiao-Hong Chen
Affiliation:
关键词: 前列腺癌;黄酮木脂素;作用机制;化疗制剂;构效关系;黄酮
摘要: Background: The generic name “flavonolignan” was created in 1968 for a relatively small class of naturally occurring hybrid molecules biogenetically originated from ubiquitous flavonoids and lignans (phenylpropanoids). The first group of flavonolignans was extracted from Silybum marianum that has long been used for hepatoprotection. Recently, the medicinal merit of flavonolignans has been extended to the prostate cancer management.
Methods: Systematic interpretation and summarization of the relevant literature.
Results: Over forty naturally occurring flavonolignans have so far been obtained from various plants. Certain flavonolignans have been demonstrated by in vitro cell-based and in vivo animal-based experiments, and human clinical studies i) to possess effective chemopreventive function against various tumor promoters; ii) to show the anti-angiogenic efficacy; iii) to have potential in treating prostate cancer; iv) to sensitize prostate tumors to chemotherapeutic agents through down-regulation of P-glycoprotein and other mechanisms; and v) to be used by prostate cancer patients to protect or treat the hepatotoxicity caused by several chemotherapies. Certain flavonolignans can synergize with well-established chemotherapeutic agents for prostate cancer.
Conclusion: This review provides a systematic and in-depth overview of the promise and potential of flavonolignans in prostate cancer management, which covers their chemopreventive effect, chemotherapeutic treatment, mechanisms of actions, synthetic derivatives, structure-activity relationships, and the difference in inhibiting prostate cancer cell proliferation between certain flavonoligans and their respective flavonoid counterpart. This summarization aims to provide valuable insights into further and rational development of flavonolignans for prostate cancer management by interpreting the data reported in the literature.
Export Options
About this article
Cite this article as:
Bao Vue, Qiao-Hong Chen , The Potential of Flavonolignans in Prostate Cancer Management, Current Medicinal Chemistry 2016; 23 (34) . https://dx.doi.org/10.2174/0929867323666160823151833
DOI https://dx.doi.org/10.2174/0929867323666160823151833 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Deciphering the Antibodyome - Peptide Arrays for Serum Antibody Biomarker Diagnostics
Current Proteomics Lipoxygenase Inhibitors for Cancer Prevention: Promises and Risks
Current Pharmaceutical Design Synthesis and Characterization of 3β-Substituted Amides of 17a-Aza-Dhomo- 4-androsten-17-one as Potent 5α-Reductase Inhibitors and Antimicrobial Agents
Current Topics in Medicinal Chemistry Clinical Development of MET Targeted Therapy For Human Cancer
Current Cancer Therapy Reviews Update of QSAR & Docking & Alignment Studies of the DNA Polymerase Inhibitors
Current Bioinformatics Biological Rationale for Regular Physical Exercise as an Effective Intervention for the Prevention and Treatment of Depressive Disorders
Current Pharmaceutical Design Alternative Splice Variants of Survivin as Potential Targets in Cancer
Current Drug Discovery Technologies The Skeletal Effects of Gonadotropin-Releasing Hormone Antagonists: A Concise Review
Endocrine, Metabolic & Immune Disorders - Drug Targets The Adipocyte as a Novel TSH Target
Mini-Reviews in Medicinal Chemistry New Molecular and Cellular Targets for Chemoprevention and Treatment of Skin Tumors by Plant Polyphenols: A Critical Review
Current Medicinal Chemistry Role of Angiopoietin-like 4 (ANGPTL4), a Member of Matricellular Proteins: from Homeostasis to Inflammation and Cancer Metastasis
Current Angiogenesis (Discontinued) Natural Products as Anticancer Agents
Current Drug Targets Aging and DNA Methylation
Current Chemical Biology Focal Adhesion Kinase Controls Prostate Cancer Progression Via Intrinsic Kinase and Scaffolding Functions
Anti-Cancer Agents in Medicinal Chemistry The Polyamine Pathway as a Potential Target for Vascular Diseases: Focus on Restenosis
Current Vascular Pharmacology Editorial (Thematic Issue: PET/CT in External Beam Radiation Therapy Dose Planning)
Current Radiopharmaceuticals Common Pathways in Health Benefit Properties of RSV in Cardiovascular Diseases, Cancers and Degenerative Pathologies
Current Pharmaceutical Biotechnology Central and Peripheral Pain Generators in Women with Chronic Pelvic Pain: Patient Centered Assessment and Treatment
Current Rheumatology Reviews The Molecular Mechanisms of Thalidomide Teratogenicity and Implications for Modern Medicine
Current Molecular Medicine Anticancer Potential of Dietary Natural Products: A Comprehensive Review
Anti-Cancer Agents in Medicinal Chemistry